AI inside validated environments, with the traceability a submission requires
In life sciences the question is never only whether the output is right. It is whether you can demonstrate, years later, how it was produced, who approved it, and that the system was in a validated state at the time.
The pressure
What is forcing the pace in life sciences
- Trial timelines and submission volumes are growing faster than regulatory writing and data management capacity.
- Commercial content review cycles limit how fast field and digital teams can move.
- Pharmacovigilance case volume grows with every approval and every market.
The constraint
What the work has to satisfy
- GxP validation and computer software assurance apply: intended use, risk assessment, and documented qualification before a system supports regulated work.
- 21 CFR Part 11 governs electronic records and signatures — audit trails, access control and record integrity are structural requirements, not features.
- Promotional content must clear medical, legal and regulatory review; AI drafting shifts where the work happens, never who signs.
- Data integrity expectations (ALCOA+) mean generated content must be attributable, legible, contemporaneous, original and accurate.
Where we start
The workflows that pay first
High volume, high variance, and far enough from the consequential decision that automation is defensible.
Regulatory and medical writing support
Structured drafting from validated source data, with full traceability from statement back to study output.
MLR content acceleration
Pre-review checks against claims libraries and prior approvals, reducing review rounds without bypassing the committee.
Pharmacovigilance case intake
Triage, duplicate detection and narrative drafting with qualified-person review retained.
Clinical data reconciliation
Anomaly surfacing across EDC and vendor data, with every flag evidenced.
How the practices apply
Our five practices, read for life sciences
- Navigate
- Determine intended use and GxP impact before scoping, so validation effort is known at funding time rather than discovered later.
- Deploy
- Build with qualification artifacts produced alongside the system, not retrofitted before an inspection.
- Amplify
- Place talent trained on where generative tooling may and may not touch submission-bound content.
- Measure
- Cycle time per document, review rounds avoided, and quality events — tracked against a pre-AI baseline.
- Sustain
- Periodic review, revalidation triggers and change control that keep the system in a qualified state.
Proof
Life sciences engagements
Situation, approach, what we built, and the constraint the solution had to satisfy.
Roles we deploy
Who shows up
- Validation Analyst
- Software Engineer
- QA Automation Engineer
- Program Manager
Next step
Book an AI readiness review for life sciences
Four weeks, one ranked opportunity register, and a governance structure your risk function can live with.
Start the conversation